GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 339-345

  Hu, Jin Song ^a   Wu, De Wu ^a   Liang, Shuo ^b   Miao, Xiong Yin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SHANGHAI PULMONARY HOSPITAL   (China)

Author keywords

Alpha fetoprotein; Golgi protein 73; Hepatocellular carcinoma; RT PCR; Western blot

Indexed keywords

ALPHA FETOPROTEIN; CELL PROTEIN; GOLGI PROTEIN 73; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASIAN; CONTROLLED STUDY; DENSITOMETRY; DIAGNOSTIC VALUE; ENDEMIC DISEASE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOASSAY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; ENDEMIC DISEASES; FEMALE; GLYCOPROTEINS; GOLGI APPARATUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77956921541     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9215-y     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin. 2005;55:74-108. doi:10.3322/canjclin. 55.2.74.
2. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005-14. doi:10.1053/j.gastro.2003.12.049. (Pubitemid 38451172)
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17. doi:10.1016/S0140-6736(03)14964-1. (Pubitemid 37518510)
4. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology. 2004;127(Suppl 51):S113-9. doi:10.1053/j.gas tro.2004.09.024.
5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management on hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421-30. doi:10.1016/S0168- 8278(01)00130-1. (Pubitemid 32844200)
6. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273-8. doi:10.1002/hep.510270140. (Pubitemid 28041564)
7. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology. 1986;6:729-38. doi:10.1002/hep.1840060432.
8. Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001;34: 603-5. doi:10.1016/S0168-8278(01)00025-3. (Pubitemid 32328519)
9. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36. doi:10.1002/hep.20933. (Pubitemid 43112690)
10. Kladney RD, Bulla GA, Guo L, et al. GP73, a novel Golgilocalized protein upregulated by viral infection. Gene. 2000;249: 53-65. doi:10.1016/S0378- 1119(00)00136-0. (Pubitemid 30300752)
11. Maitra A, Thuluvath PJ. GP73 and liver disease: a (Golgi) complex enigma.AmJ Gastroenterol. 2004;99:1096-8. doi:10.1111/j.1572- 0241.2004.40410.x.
12. Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43:1007-12. doi:10.1016/j.jhep.2005. 05.028.
13. Schwegler EE, Cazares L, Steel LF, et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology. 2005;41:634-42. doi:10.1002/hep.20577. (Pubitemid 40289513)
14. Iftikhar R, KladneyRD, HavliogluN, et al. Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol. 2004;99:1087-95. doi:10.1111/j.1572-0241.2004.30572.x. (Pubitemid 38917813)
15. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 2002;35:1431-40. doi:10.1053/jhep. 2002.32525.
16. Kladney RD, Tollefson AE, Wold WS, Fimmel CJ. Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain. Virology. 2002;301:236-46. doi: 10.1006/viro.2002.1523. (Pubitemid 35176548)
17. Chinese Society of Hepatology. 2004 Guidelines for surgical treatment of primary hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2005;13:329-30.
18. Chinese Society of Infectious Diseases. The guidelines of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2005;13:881-91.
19. Chinese Medical Association. Guideline of prevention and treatment of hepatitis C. Zhonghua Yu Fang Yi Xue Za Zhi. 2004; 38: 210-5.
20. Metz CEhB, Shen JH. Maximum-likelihood estimation of receiver operating characteristic (ROC) curves from continuously distributed data. Stat Med. 1998;17:1033-53. doi:10.1002/(SICI)1097- 0258(19980515)17:9<1033::AID- SIM784>3.0.CO;2-Z.
21. Cassandra Willyard. Researchers look for 'aweet' method to diagnose cancer. Nat Med. 2007;13:1267. doi:10.1038/nm1107- 1267. (Pubitemid 350073572)
22. Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein convertase cleavage of cis golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic. 2007;8: 1415-23. doi:10.1111/j.1600-0854.2007.00621.x. (Pubitemid 47394245)
23. Lorinda MW, Sheri Y, Maria MP. Decreased survival and hepatorenal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol. 2009;2:34-47.